Skip to main content

Research Repository

Advanced Search

Effectiveness and cost effectiveness of daily all over body application of emollient during the first year of life for preventing atopic eczema in high risk children (The BEEP trial): protocol for a randomised controlled trial

Chalmers, Joanne R.; Haines, Rachel H.; Mitchell, Eleanor J.; Thomas, Kim S.; Brown, Sara J.; Ridd, Matthew; Lawton, Sandra; Simpson, Eric L.; Cork, Michael J.; Sach, Tracey H.; Bradshaw, Lucy E.; Montgomery, Alan A.; Boyle, Robert J.; Williams, Hywel C.

Effectiveness and cost effectiveness of daily all over body  application of emollient during the first year of life for preventing atopic eczema in high risk children (The BEEP trial): protocol for a randomised controlled trial Thumbnail


Authors

Joanne R. Chalmers

Rachel H. Haines

Sara J. Brown

Matthew Ridd

Sandra Lawton

Eric L. Simpson

Michael J. Cork

Tracey H. Sach

ALAN MONTGOMERY ALAN.MONTGOMERY@NOTTINGHAM.AC.UK
Director Nottingham Clinical Trials Unit

Robert J. Boyle

Profile Image

HYWEL WILLIAMS HYWEL.WILLIAMS@NOTTINGHAM.AC.UK
Professor of Dermato-Epidemiology



Abstract

Background: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis. AE treatment is a significant cost burden for healthcare providers. The purpose of the trial is to investigate whether daily application of emollients for the first year of life can prevent AE developing in high risk infants (first degree relative with asthma, AE or allergic rhinitis).

Methods: This is a protocol for a pragmatic two-arm randomised controlled, multicentre trial. Up to 1400 term infants at high risk of developing AE will be recruited through the community, primary and secondary care in England. Participating families will be randomised in a 1:1 ratio to receive general infant skin care advice, or general skin care advice plus emollients with advice to apply daily to the infant for the first year of life. Families will not be blinded to treatment allocation. The primary outcome will be a blinded assessment of AE at 24 months of age using the UK working party diagnostic criteria. Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and have fever, allergic sensitisation, quality of life, cost effectiveness and safety of the emollients. Subgroup analyses are planned for the primary outcome according to filaggrin genotype and the number of first degree relatives with AE and other atopic diseases. Families will be followed up by online and postal questionnaire at 3, 6, 12, 18 months with a face-to-face visit at 24 months. Long term follow up until 60 months will be via annual questionnaires.
Discussion: This trial will demonstrate whether skin barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high risk infants. If effective, this simple and cheap intervention has the potential to result in significant cost savings for healthcare providers throughout the world by preventing AE and possibly other associated allergic diseases.

Journal Article Type Article
Acceptance Date May 31, 2017
Online Publication Date Jul 21, 2017
Publication Date Jul 21, 2017
Deposit Date Jul 19, 2017
Publicly Available Date Jul 21, 2017
Journal Trials
Electronic ISSN 1745-6215
Publisher Springer Verlag
Peer Reviewed Peer Reviewed
Volume 18
Issue 1
Article Number 343
DOI https://doi.org/10.1186/s13063-017-2031-3
Keywords Protocol, randomised controlled trial, eczema, atopic dermatitis, prevention, emollient, barrier enhancement, filaggrin, core outcomes
Public URL https://nottingham-repository.worktribe.com/output/873335
Publisher URL https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2031-3

Files


Effectiveness and cost effectiveness of daily all over body application of emollient during the first year of life for preventing atopic eczema in hig.pdf (553 Kb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0





You might also like



Downloadable Citations